Seeking safe stool: Canada needs a universal donor model

CMAJ

Volumn 188, Issue 17-18, 2016, Pages E431-E432

  Edelstein, Carolyn ^a   Daw, Jamie R ^b   Kassam, Zain ^a,c  

^a OpenBiome   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM IDENTIFICATION; CANADA; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; DATA ANALYSIS; DISEASE ASSOCIATION; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; HUMAN; MEDICAL SOCIETY; NOTE; PATIENT SAFETY; SCREENING TEST; BIOBANK; DIRECTED TISSUE DONATION; DONOR; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HEALTH CARE POLICY; PHYSICIAN ATTITUDE; PROCEDURES; RECURRENT DISEASE;

BIOLOGICAL SPECIMEN BANKS; CANADA; DIRECTED TISSUE DONATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; HEALTH POLICY; HUMANS; PHYSICIAN'S ROLE; RECURRENCE; TISSUE DONORS;

EID: 85002252351     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.150672     Document Type: Note

References (13)

1. Guidance document: regulation of fecal microbiota therapy for the treatment of C. difficile infections. Ottawa: Health Canada; 2015. Available: www.hc-sc.gc.ca/dhp-mps/consultation/biolog/fecal-microbiota-bacterio-fecale-eng.php (accessed 2015 Apr. 11).
2. Kassam Z, Lee CH, Hunt RH. Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges. Clin Lab Med 2014;34:787-98.
3. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
4. Edelstein CA, Kassam Z, Daw J, et al. The regulation of fecal microbiota for transplantation: an international perspective for policy and public health. Clin Res Regul Aff 2015;32:101-9.
5. Moayyedi P, Marshall JK, Yuan Y, et al. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. Can J Gastroenterol Hepatol 2014;28:66-8.
6. Levy AR, Szabo SM, Lozano-Ortega G, et al. Incidence and costs of Clostridium difficile infections in Canada. Open Forum Infect Dis 2015;2(3):ofv076.
7. Clostridium difficile infection: infection prevention and control guidance for management in acute care settings. Ottawa: Public Health Agency of Canada; 2013. Available: www.phac-aspc.gc.ca/nois-sinp/guide/c-dif-acs-esa/index-eng.php (accessed 2015 June 2).
8. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500-8.
9. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostrid-ium difficile infection. Am J Gastroenterol 2012;107:1079-87.
10. Dubois N, Ling K, Osman M, et al. Prospective assessment of donor eligibility for fecal microbiota transplantation at a public stool bank results from the evaluation of 1387 candidate donors [abstract]. IDWeek 2015 meeting; 2015 Oct. 7-11; San Diego.
11. Carmeli Y, Venkataraman L, DeGirolami PC, et al. Stool colonization of healthcare workers with selected resistant bacteria. Infect Control Hosp Epidemiol 1998;19:38-40.
12. Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther 2015;42:1011-8.
13. Konijeti GG, Sauk J, Shrime MG, et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;58:1507-14.